CanVIG-UK Resources
Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant
Approved: May 2022
Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant
Approved: May 2022
Example predictive testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)
Approved: May 2022
​
Example predictive testing template for reporting a positive BRCA1 or PALB2 germline pathogenic/likely pathogenic variant
Approved: May 2022
Previous version: June 2021
Example predictive testing template for reporting a positive BRCA2 germline pathogenic/likely pathogenic variant
Approved: May 2022
Previous version: June 2021
Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant
Approved: May 2022
Previous version (BRCA only): June 2021
Example predictive testing template for reporting a negative variant for the R208 germline panel
Approved: May 2022
Previous version: June 2021
Example diagnostic testing template for reporting a CHEK2 or ATM germline pathogenic/likely pathogenic variant.
Approved: May 2022
Example diagnostic testing template for reporting ATM c.7271T>G p.(Val2424Gly)
Approved: May 2022
Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.
Approved: May 2022
Previous version (BRCA only): June 2021
Example diagnostic testing template for reporting a reduced penetrance BRCA or PALB2 germline pathogenic/likely pathogenic variant.
Approved: May 2022
​
Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.
Approved: May 2022
​
Example diagnostic testing template for reporting where a variant of uncertain significance (VUS) is identified in the R208 panel (including CHEK2 and ATM)
Approved: May 2022
Previous version (BRCA only): June 2021
Example diagnostic testing template for reporting no germline pathogenic/likely pathogenic variants identified in the R208 panel (including CHEK2 and ATM)
Approved: May 2022
Previous version (BRCA only): June 2021
Example template for reporting a germline pathogenic/likely pathogenic variant in the Ovarian Cancer R207 diagnostic panel.
Approved: June 2022
Previous version: June 2021
Example template for reporting a germline variant of uncertain significance in the Ovarian Cancer R207 diagnostic panel.
Approved: June 2022
​
Example template for reporting no germline pathogenic/likely pathogenic variants in the Ovarian Cancer R207 diagnostic panel.
Approved: June 2022
​
Example template for reporting a germline pathogenic/likely pathogenic variant in the Prostate Cancer R430 diagnostic panel.
Approved: September 2023
​
Example template for reporting a germline variant of uncertain significance in the Prostate Cancer R430 diagnostic panel.
Approved: September 2023
​
Example template for reporting no germline pathogenic/likely pathogenic variants in the Prostate Cancer R430 diagnostic panel.
Approved: September 2023
Example diagnostic testing template for reporting a reduced penetrance germline pathogenic/likely pathogenic variant in the Prostate Cancer R430 diagnostic panel.
Approved: September 2023
​
Example Report Templates
External Resources
ACGS
The Association for Clinical Genomic Science brings together scientists working within genetics into one professional association.
JMG Paper
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network.
Journal of Medical Genetics
Published: 13 March 2020.
UKCGG
The UK Cancer Genetics Group.
​
A multidisciplinary organisation for UK clinicians, counsellors & scientists interested in cancer susceptibility genetics.
ACMG
The American College of Medical Genetics variant interpretation framework can be found on their website.